Physician profile
Nathan Smith
NPI 1376037697
$713.83
in general payments reported to CMS, 2019-2025
13 companies · $83.39 in 2025
The $83.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.32 · 2021: $12.00 · 2022: $482 · 2023: $37.92 · 2024: $75.76 · 2025: $83.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $364.84 | 2022 | |
| Glaxosmithkline, LLC. | $78.16 | 2024-2025 | Arexvy, Shingrix |
| Stimwave Technologies Incorporated | $69.74 | 2022 | |
| Scilex Pharmaceuticals INC. | $24.49 | 2022 | |
| Novo Nordisk INC | $23.99 | 2025 | Ozempic, Rybelsus |
| Bioventus LLC | $23.37 | 2022 | |
| Sanofi Pasteur INC. | $22.32 | 2019 | |
| Globus Medical, INC. | $21.76 | 2025 | Vyrsa V1 |
| Inspire Medical Systems, INC. | $21.65 | 2025 | Inspire |
| Abbvie INC. | $19.35 | 2023 | Vraylar |
| Collegium Pharmaceutical, INC. | $18.57 | 2023 | Belbuca |
| Amgen INC. | $13.59 | 2024 | Otezla, Repatha |
| Biodelivery Sciences International, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.